Effect of chronic exposure to fine particulate matter on cardiac tissue of NZBWF1 mice

Imagem de Miniatura
Arquivos
art_WAKED_Effect_of_chronic_exposure_to_fine_particulate_matter_2023.PDF (2.66 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, v.104, n.4, p.177-187, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Epidemiological and toxicological studies have shown that inhalation of particulate matter (PM) is associated with development of cardiovascular diseases. Long-term exposure to PM may increase the risk of cardiovascular events and reduce life expectancy. Systemic lupus erythematosus (SLE) is a chronic inflammatory disease, autoimmune in nature, that is characterized by the production of autoantibodies that affects several organs, including the heart. Air pollution - which can be caused by several different factors - may be one of the most important points both at the onset and the natural history of SLE. Therefore this study aims to investigate whether exposure to air pollution promotes increased inflammation and cardiac remodelling in animals predisposed to SLE. Female NZBWF1 mice were exposed to an environmental particle concentrator. Aspects related to cardiac remodelling, inflammation and apoptosis were analysed in the myocardium. Body weight gain, cardiac trophism by heart/body weight ratio, relative area of cardiomyocytes and the fibrotic area of cardiac tissue were evaluated during the exposure period. Animals exposed to PM2.5 showed increased area of cardiomyocytes, and area of fibrosis; in addition, we observed an increase in IL-1 and C3 in the cardiac tissue, demonstrating increased inflammation. We suggest that air pollution is capable of promoting cardiac remodelling and increased inflammation in animals predisposed to SLE.
Palavras-chave
air pollution, autoimmune disease, cardiac remodelling, cardiovascular diseases, particulate matter, systemic lupus erythematosus
URI
https://observatorio.fm.usp.br/handle/OPI/54961
Referências
  1. ACCINNI L, 1979, AM J PATHOL, V96, P477
  2. Al-Herz A, 2003, J RHEUMATOL, V30, P493
  3. Almaani S, 2017, CLIN J AM SOC NEPHRO, V12, P825, DOI 10.2215/CJN.05780616
  4. An RP, 2018, PERSPECT PUBLIC HEAL, V138, P111, DOI 10.1177/1757913917726567
  5. Belotti L., 2012, THESIS SAO PAULO
  6. Bonilla JPR., 2009, INHAL TOXICOL, V22, P330
  7. Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8
  8. Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
  9. BUDMAN DR, 1976, ARCH INTERN MED, V136, P1003, DOI 10.1001/archinte.136.9.1003
  10. Cancado J., 2006, J BRAS PNEUMOL, V32 Suppl 2, pS5, DOI [10.1590/S1806-37132006000800003, DOI 10.1590/S1806-37132006000800003]
  11. Chaiamnuay S, 2007, ANN RHEUM DIS, V66, P618, DOI 10.1136/ard.2006.059311
  12. Cojocaru Manole, 2011, Maedica (Bucur), V6, P330
  13. Colasanti T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1111-y
  14. Costa RD., 2008, BRAS MED, V41, P41
  15. Daniel L, 2001, KIDNEY INT, V60, P2215, DOI 10.1046/j.1523-1755.2001.00055.x
  16. Deschenes O, 2020, J DEV ECON, V145, DOI 10.1016/j.jdeveco.2020.102461
  17. Di Domenico M, 2020, NEUROTOXICOLOGY, V79, P127, DOI 10.1016/j.neuro.2020.05.004
  18. EPA (Environmental Protection Agency), 2020, EXPOSURE ASSESSMENT
  19. Alves AGF, 2018, CLIN RHEUMATOL, V37, P683, DOI 10.1007/s10067-017-3893-1
  20. Finch J, 2019, AIMS ENVIRON SCI, V6, P265, DOI [10.3934/environsci.2019.4.265, 10.3934/environsci.2019.6.265]
  21. Fonken LK, 2011, MOL PSYCHIATR, V16, P987, DOI 10.1038/mp.2011.76
  22. Franck U, 2011, SCI TOTAL ENVIRON, V409, P4217, DOI 10.1016/j.scitotenv.2011.05.049
  23. Fuchs L., 2014, THESIS U SAO PAULO S
  24. Gasques L. S., 2013, Arquivos de Ciencias da Saude da UNIPAR, V17, P49
  25. Gawalko M, 2020, CIRC J, V84, P685, DOI 10.1253/circj.CJ-19-0705
  26. Glovsky MM, 2004, ANN ALLERG ASTHMA IM, V93, P513, DOI 10.1016/S1081-1206(10)61257-4
  27. Gomes MJ, 2008, ABCD-ARQ BRAS CIR DI, V21, P33, DOI 10.1590/S0102-67202008000100007
  28. Goodman PG, 2004, ENVIRON HEALTH PERSP, V112, P179, DOI 10.1289/ehp.6451
  29. Hamza Ilham Ganem, 2020, Biochemical and Cellular Archives, V20, P1179, DOI 10.35124/bca.2020.20.1.1179
  30. Heyes A, 2019, J ENVIRON ECON MANAG, V98, DOI 10.1016/j.jeem.2019.07.002
  31. Host S, 2008, OCCUP ENVIRON MED, V65, P544, DOI 10.1136/oem.2007.036194
  32. Hsieh YL, 2013, INHAL TOXICOL, V25, P455, DOI 10.3109/08958378.2013.804609
  33. Hsu HC, 2008, NAT IMMUNOL, V9, P166, DOI 10.1038/ni1552
  34. Jain D, 2009, J CLIN PATHOL, V62, P584, DOI 10.1136/jcp.2009.064311
  35. Jesus Adriana Almeida de, 2012, Rev. Bras. Reumatol., V52, P976, DOI 10.1590/S0482-50042012000600015
  36. Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58
  37. Kim KH, 2015, ENVIRON INT, V74, P136, DOI 10.1016/j.envint.2014.10.005
  38. Lazou A, 2020, BRIT J PHARMACOL, V177, P5357, DOI 10.1111/bph.14975
  39. Lim SS, 2014, ARTHRITIS RHEUMATOL, V66, P357, DOI 10.1002/art.38239
  40. MANDELL BF, 1987, SEMIN ARTHRITIS RHEU, V17, P126, DOI 10.1016/0049-0172(87)90035-7
  41. Marcon CR., 2004, REV BRAS REUMATOL, V44, P5
  42. Sabio JM, 2011, J RHEUMATOL, V38, P1026, DOI 10.3899/jrheum.101132
  43. Mizui M, 2020, AUTOIMMUNE DISEASES, 6TH EDITION, P533, DOI 10.1016/B978-0-12-812102-3.00029-4
  44. Mota D., 2014, 101 NCIA NATURA SANT, V36, P258
  45. Petri M, 2000, LUPUS, V9, P170, DOI 10.1191/096120300678828226
  46. Petrin J, 1993, Blood Press, V2, P108, DOI 10.3109/08037059309077537
  47. Putinski C., 2013, P NATL ACAD SCI USA, V43, P110
  48. Robert M, 2020, LUPUS, V29, P6, DOI 10.1177/0961203319891243
  49. Sabio JM, 2001, LUPUS, V10, P451, DOI 10.1191/096120301678646227
  50. Sanghera C, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.036947
  51. Schoenfeld SR, 2013, SEMIN ARTHRITIS RHEU, V43, P77, DOI 10.1016/j.semarthrit.2012.12.002
  52. Selzer F, 2001, HYPERTENSION, V37, P1075, DOI 10.1161/01.HYP.37.4.1075
  53. Shaharir SS, 2015, INT J RHEUM DIS, V18, P541, DOI 10.1111/1756-185X.12474
  54. Shahrbaf MA, 2021, CURR PROB CARDIOLOGY, V46, DOI 10.1016/j.cpcardiol.2020.100649
  55. Shin JI, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.06.010
  56. Silva HCL., 2011, ARQ MED HOSP FAC CIE, V56, P122
  57. SIOUTAS C, 1995, ENVIRON HEALTH PERSP, V103, P172, DOI 10.2307/3432274
  58. Stubbins RE, 2012, EUR J NUTR, V51, P861, DOI 10.1007/s00394-011-0266-4
  59. Sun Y., 2018, PLOS ONE, V13
  60. Tang WZ, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0783-1
  61. Torres T, 2014, ACTA MEDICA PORT, V27, P252, DOI 10.20344/amp.4777
  62. Tsai DH, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-24
  63. Utiyama Shirley Ramos da Rosa, 2004, Rev. Bras. Reumatol., V44, P277, DOI 10.1590/S0482-50042004000400006
  64. Valiatti FB, 2011, ARQ BRAS ENDOCRINOL, V55, P106, DOI 10.1590/S0004-27302011000200002
  65. Varella PPV, 2001, REV BRAS ALERGIA IMU, V24, P146
  66. Wang Q, 2019, INT J BIOL SCI, V15, P24, DOI 10.7150/ijbs.28633
  67. WARD MM, 1992, ARCH INTERN MED, V152, P2082, DOI 10.1001/archinte.152.10.2082
  68. Willis R, 2017, LUPUS, V26, P1517, DOI 10.1177/0961203317706557
  69. Wold LE, 2012, CIRC-HEART FAIL, V5, P452, DOI 10.1161/CIRCHEARTFAILURE.112.966580
  70. WORLD, AIR POLL
  71. Yang XZ, 2019, ENVIRON INT, V127, P601, DOI 10.1016/j.envint.2019.03.057
  72. Yang ZM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16214296
  73. Yariwake VY, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00407-0
  74. Yee CS, 2015, RHEUMATOLOGY, V54, P836, DOI 10.1093/rheumatology/keu412
  75. Ying ZK, 2009, AM J PHYSIOL-HEART C, V296, pH1540, DOI 10.1152/ajpheart.01270.2008
  76. Akinaga LMY, 2009, TOXICOL PATHOL, V37, P306, DOI 10.1177/0192623309332994

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - ODS/03